Peter L. Anderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter L. Anderson has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Jia-Hua Zheng
Department of Pharmaceutical Sciences, University of Colorado Denver, Denver, CO, USA
2 shared publicationsKenneth A. Lichtenstein
Department of Medicine, University of Colorado Health Sciences Center, Denver
2 shared publicationsThomas N. Kakuda
Human Pharmacokinetics, Tibotec Inc. 1020 Stony Hill Road, Suite 300, Yardley, PA 19067, USA
2 shared publicationsTracy King
Department of Pharmaceutical Sciences, University of Colorado Denver, Denver, CO, USA
2 shared publicationsAmie Meditz
1 shared publicationCourtney V Fletcher
1 shared publication
Latest Publications
- Open Access
- 20 June 2008
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (4) , 738-745
Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro
Elevated zidovudine- and lamivudine-triphosphates have been observed in peripheral blood mononuclear cells (PBMCs) from females versus males and in patients with high inflammatory states versus lower inflammatory states. Consistent with high triphosphate exposures, these same patient groups also experience elevated rates of toxicity, including lipoatrophy. The purpose of this study was to evaluate the effects of oestradiol, progesterone and testosterone as well as tumour necrosis factor (TNF)-α and interferon (IFN)-α on zidovudine- and lamivudine-triphosphates in PBMCs and, for the cytokines, in 3T3-L1 adipocytes. Multiple replicates of adipocytes and human PBMCs were incubated with experimental versus control conditions using several cytokine and sex hormone doses. Zidovudine- and lamivudine-triphosphate concentrations were determined with validated LC-MS-MS assays. A mixed effects, cell means model that accounted for experiment number was used to evaluate the effects of experimental conditions relative to control. In adipocytes, TNF-α doses below 2 ng/mL increased zidovudine-triphosphate by 18% (5–31%). Lamivudine-triphosphate was not detectable in adipocytes. In PBMCs, pooled IFN-α doses (0.1–10 U/mL) decreased zidovudine-triphosphate 26% (10–42%); 100 and 1000 ng/mL of progesterone decreased lamivudine-triphosphate by 22% (1–43%) and 47% (25–68%), respectively. Pooled testosterone doses (10–1000 ng/mL) decreased lamivudine-triphosphate by 24% (7–41%). No other statistically significant effects were observed. We found evidence that sex hormones and cytokines influence zidovudine-triphosphate and lamivudine-triphosphate slightly in PBMCs and adipocytes in vitro. These findings provide insight and scientific direction to address inflammation-dependent and sex-dependent phosphorylation and responses in patients.
- 20 June 2008
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (4) , 738-745
Open AccessCytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro
Elevated zidovudine- and lamivudine-triphosphates have been observed in peripheral blood mononuclear cells (PBMCs) from females versus males and in patients with high inflammatory states versus lower inflammatory states. Consistent with high triphosphate exposures, these same patient groups also experience elevated rates of toxicity, including lipoatrophy. The purpose of this study was to evaluate the effects of oestradiol, progesterone and testosterone as well as tumour necrosis factor (TNF)-α and interferon (IFN)-α on zidovudine- and lamivudine-triphosphates in PBMCs and, for the cytokines, in 3T3-L1 adipocytes. Multiple replicates of adipocytes and human PBMCs were incubated with experimental versus control conditions using several cytokine and sex hormone doses. Zidovudine- and lamivudine-triphosphate concentrations were determined with validated LC-MS-MS assays. A mixed effects, cell means model that accounted for experiment number was used to evaluate the effects of experimental conditions relative to control. In adipocytes, TNF-α doses below 2 ng/mL increased zidovudine-triphosphate by 18% (5–31%). Lamivudine-triphosphate was not detectable in adipocytes. In PBMCs, pooled IFN-α doses (0.1–10 U/mL) decreased zidovudine-triphosphate 26% (10–42%); 100 and 1000 ng/mL of progesterone decreased lamivudine-triphosphate by 22% (1–43%) and 47% (25–68%), respectively. Pooled testosterone doses (10–1000 ng/mL) decreased lamivudine-triphosphate by 24% (7–41%). No other statistically significant effects were observed. We found evidence that sex hormones and cytokines influence zidovudine-triphosphate and lamivudine-triphosphate slightly in PBMCs and adipocytes in vitro. These findings provide insight and scientific direction to address inflammation-dependent and sex-dependent phosphorylation and responses in patients.
- 1 May 2008
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 3 (3) , 258-265
Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs
This review summarizes recent developments regarding the unique clinical pharmacologic profile of nucleoside analog reverse transcriptase inhibitors for management of HIV. First, intracellular data in patients suggest that nucleoside reverse transcriptase inhibitor-triphosphates are compartmentalized in different cell types. Additionally, intracellular drug-drug interactions were identified, which were undetectable in plasma. Second, extracellular data illustrate multiple bidirectional plasma drug-drug interactions between renally eliminated tenofovir and liver-metabolized drugs. Definitive mechanistic details for these interactions are lacking but they appear to involve renal and/or enteric drug transporters. Furthermore, the plasma versus female genital tract disposition of these agents was recently elucidated, which is important for currently investigated indications for pre-exposure and post-exposure prophylaxis. Finally, tenofovir/emtricitabine and abacavir (using a promising human leukocyte antigen-B*5701 genetic test for hypersensitivity)/lamivudine have emerged as common first-line nucleoside analog reverse transcriptase inhibitors because of co-formulations, once-daily dosing, and favorable tolerability and adverse effect profiles. Nevertheless, elucidating the long-term safety profile for all nucleoside analog reverse transcriptase inhibitors remains a priority. Knowledge of nucleoside analog reverse transcriptase inhibitor disposition intracellularly and extracellularly has expanded. This provides a basis for rational use of these agents clinically and adds new perspectives for future research.
- 1 May 2008
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 3 (3) , 258-265
Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs
This review summarizes recent developments regarding the unique clinical pharmacologic profile of nucleoside analog reverse transcriptase inhibitors for management of HIV. First, intracellular data in patients suggest that nucleoside reverse transcriptase inhibitor-triphosphates are compartmentalized in different cell types. Additionally, intracellular drug-drug interactions were identified, which were undetectable in plasma. Second, extracellular data illustrate multiple bidirectional plasma drug-drug interactions between renally eliminated tenofovir and liver-metabolized drugs. Definitive mechanistic details for these interactions are lacking but they appear to involve renal and/or enteric drug transporters. Furthermore, the plasma versus female genital tract disposition of these agents was recently elucidated, which is important for currently investigated indications for pre-exposure and post-exposure prophylaxis. Finally, tenofovir/emtricitabine and abacavir (using a promising human leukocyte antigen-B*5701 genetic test for hypersensitivity)/lamivudine have emerged as common first-line nucleoside analog reverse transcriptase inhibitors because of co-formulations, once-daily dosing, and favorable tolerability and adverse effect profiles. Nevertheless, elucidating the long-term safety profile for all nucleoside analog reverse transcriptase inhibitors remains a priority. Knowledge of nucleoside analog reverse transcriptase inhibitor disposition intracellularly and extracellularly has expanded. This provides a basis for rational use of these agents clinically and adds new perspectives for future research.
- 1 September 2007
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (14) , 1849-1854
Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults
Concentrations of zidovudine (ZDV)- and lamivudine (3TC)-triphosphates (TP) have been quantified in unfractionated peripheral blood mononuclear cells (PBMC) from HIV+ patients. The objective of this study was to determine whether concentrations of ZDV-TP and 3TC-TP in PBMC reflect the concentrations within CD4 T cells in HIV-seronegative adults. Volunteers had taken 300 mg of ZDV plus 150 mg of 3TC twice daily for ≥ 7 days. Blood (60 mL) was collected 2 or 5 h post observed dose. PBMC were processed into three cell fractions using CD4 magnetic immunobeads: CD4-purified cells; unfractionated PBMC; and CD4-depleted PBMC. TP were determined in each cell fraction with liquid chromatography–mass spectrometry and compared across cell types by non-parametric analyses. Six males and two females participated. The median (range) percentage of CD4 T cells (CD4%) in each fraction were: CD4-purified, 99%; unfractionated, 63% (range, 53–70); and CD4-depleted, 14% (range, 4–29). Corresponding median (range) ZDV-TP concentrations were 8.0 (5.3–10.3), 26.5 (12.9–42.2), and 34.2 (16.4–52.2) fmol/1 × 106 cells (Friedman P = 0.0008). The 3TC-TP values were 4.6 (2.3–6.7), 4.8 (3.5–8.8), and 6.8 (4.0–13.1) pmol//1 × 106 cells (Friedman P = 0.01). In mixed model analyses: ZDV-TP (fmol/1 × 106 cells) = 42–0.32 (CD4%); P < 0.001 and 3TC-TP (pmol/1 × 106 cells) = 7.3–0.03(CD4%); P = 0.003. In HIV-seronegative volunteers, 3TC-TP concentrations in PBMC reflected the concentrations within CD4 T cells, but ZDV-TP concentrations were more than 70% lower in CD4 T cells than in PBMC. Thus, TP concentrations differ according to cell type in vivo with corresponding efficacy and toxicity implications for cells with low or high triphosphates.
- 1 September 2007
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (14) , 1849-1854
Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults
Concentrations of zidovudine (ZDV)- and lamivudine (3TC)-triphosphates (TP) have been quantified in unfractionated peripheral blood mononuclear cells (PBMC) from HIV+ patients. The objective of this study was to determine whether concentrations of ZDV-TP and 3TC-TP in PBMC reflect the concentrations within CD4 T cells in HIV-seronegative adults. Volunteers had taken 300 mg of ZDV plus 150 mg of 3TC twice daily for ≥ 7 days. Blood (60 mL) was collected 2 or 5 h post observed dose. PBMC were processed into three cell fractions using CD4 magnetic immunobeads: CD4-purified cells; unfractionated PBMC; and CD4-depleted PBMC. TP were determined in each cell fraction with liquid chromatography–mass spectrometry and compared across cell types by non-parametric analyses. Six males and two females participated. The median (range) percentage of CD4 T cells (CD4%) in each fraction were: CD4-purified, 99%; unfractionated, 63% (range, 53–70); and CD4-depleted, 14% (range, 4–29). Corresponding median (range) ZDV-TP concentrations were 8.0 (5.3–10.3), 26.5 (12.9–42.2), and 34.2 (16.4–52.2) fmol/1 × 106 cells (Friedman P = 0.0008). The 3TC-TP values were 4.6 (2.3–6.7), 4.8 (3.5–8.8), and 6.8 (4.0–13.1) pmol//1 × 106 cells (Friedman P = 0.01). In mixed model analyses: ZDV-TP (fmol/1 × 106 cells) = 42–0.32 (CD4%); P < 0.001 and 3TC-TP (pmol/1 × 106 cells) = 7.3–0.03(CD4%); P = 0.003. In HIV-seronegative volunteers, 3TC-TP concentrations in PBMC reflected the concentrations within CD4 T cells, but ZDV-TP concentrations were more than 70% lower in CD4 T cells than in PBMC. Thus, TP concentrations differ according to cell type in vivo with corresponding efficacy and toxicity implications for cells with low or high triphosphates.
- Open Access
- 2 May 2006
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 58 (1) , 220-221
Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
P. L. A. has received research grant support from Bristol-Myers Squibb and GlaxoSmithKline. T. N. K. is an employee of Tibotec, Inc.
- 2 May 2006
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 58 (1) , 220-221
Open AccessComment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
P. L. A. has received research grant support from Bristol-Myers Squibb and GlaxoSmithKline. T. N. K. is an employee of Tibotec, Inc.
- 1 November 2004
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 38 (11) , 1924-1934
Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy
OBJECTIVE: To contrast available once-daily antiretroviral agents and combinations of these agents from a clinical pharmacologic viewpoint. DATA SOURCES: Data were extracted from publications and major HIV conference proceedings cited in MEDLINE (1966–March 2004) using the search terms antiretroviral therapy, combination therapy, once-daily therapy, and pharmacokinetics. Additional references were obtained from the bibliographies of these sources. STUDY SELECTION AND DATA EXTRACTION: Information pertaining to pharmacologic perspectives for once-daily antiretroviral agents was selected. DATA SYNTHESIS: Maximal and durable suppression of plasma HIV RNA, the principal goal of therapy, depends on the intrinsic antiviral activity of the antiretroviral regimen. A favorable tolerability/toxicity profile is also fundamentally important. All once-daily agents exhibit some pharmacologic limitations or lack adequate long-term follow-up. Of available agents, efavirenz has a long and distinguished efficacy record, with reasonable safety and moderate tolerability. Lamivudine, and newer agents such as atazanavir (or atazanavir/ritonavir), emtricitabine, fosamprenavir/ritonavir, and tenofovir, may offer pharmacologic advantages in the current state of once-daily therapy. Important considerations exist for coadministering once-daily agents including drug–drug interactions, drug–food incompatibilities, and synergistic toxicities. Few controlled studies have compared once-daily regimens with conventional regimens. CONCLUSIONS: Progress has been made toward once-daily therapy, but more clinical experience with available agents is needed, including comparative studies of entirely once-daily regimens versus conventional regimens. Limitations of currently available agents signify a need for improved antiretroviral utilization or new alternative agents.
- 1 November 2004
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 38 (11) , 1924-1934
Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy
OBJECTIVE: To contrast available once-daily antiretroviral agents and combinations of these agents from a clinical pharmacologic viewpoint. DATA SOURCES: Data were extracted from publications and major HIV conference proceedings cited in MEDLINE (1966–March 2004) using the search terms antiretroviral therapy, combination therapy, once-daily therapy, and pharmacokinetics. Additional references were obtained from the bibliographies of these sources. STUDY SELECTION AND DATA EXTRACTION: Information pertaining to pharmacologic perspectives for once-daily antiretroviral agents was selected. DATA SYNTHESIS: Maximal and durable suppression of plasma HIV RNA, the principal goal of therapy, depends on the intrinsic antiviral activity of the antiretroviral regimen. A favorable tolerability/toxicity profile is also fundamentally important. All once-daily agents exhibit some pharmacologic limitations or lack adequate long-term follow-up. Of available agents, efavirenz has a long and distinguished efficacy record, with reasonable safety and moderate tolerability. Lamivudine, and newer agents such as atazanavir (or atazanavir/ritonavir), emtricitabine, fosamprenavir/ritonavir, and tenofovir, may offer pharmacologic advantages in the current state of once-daily therapy. Important considerations exist for coadministering once-daily agents including drug–drug interactions, drug–food incompatibilities, and synergistic toxicities. Few controlled studies have compared once-daily regimens with conventional regimens. CONCLUSIONS: Progress has been made toward once-daily therapy, but more clinical experience with available agents is needed, including comparative studies of entirely once-daily regimens versus conventional regimens. Limitations of currently available agents signify a need for improved antiretroviral utilization or new alternative agents.
- Open Access
- 15 September 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (6) , 878-879
Reply to Stevens et al
- 15 September 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (6) , 878-879
Open AccessReply to Stevens et al
- Open Access
- 1 March 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (5) , 743-753
The Cellular Pharmacology of Nucleoside‐ and Nucleotide‐Analogue Reverse‐Transcriptase Inhibitors and Its Relationship to Clinical Toxicities
Nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors (NRTIs) require intracellular phosphorylation for anti–human immunodeficiency vi
- 1 March 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (5) , 743-753
Open AccessThe Cellular Pharmacology of Nucleoside‐ and Nucleotide‐Analogue Reverse‐Transcriptase Inhibitors and Its Relationship to Clinical Toxicities
Nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors (NRTIs) require intracellular phosphorylation for anti–human immunodeficiency vi
- Open Access
- 1 February 2004
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 61 (4) , 394-396
Stability of zidovudine with oxytocin in a simulated Y-site injection
Peter L. Anderson, Pharm.D., Susan Miller, Pharm.D., Lane R. Bushman, B.S.; Stability of zidovudine with oxytocin in a simulated Y-site injection, American Jou
- 1 February 2004
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 61 (4) , 394-396
Open AccessStability of zidovudine with oxytocin in a simulated Y-site injection
Peter L. Anderson, Pharm.D., Susan Miller, Pharm.D., Lane R. Bushman, B.S.; Stability of zidovudine with oxytocin in a simulated Y-site injection, American Jou